To Evaluate The Efficacy Of The Pregnant Women With HBV Carrier By Injected Hepatitis B Virus-specific Immunoglobulin

Objective: To study if the quantitative HBV-DNA could evaluate efficiently the maternal-infant transmission of HBV interrupted by HBIG injected at 7,8,9 months of pregnancy in HBV carrier mothers. Methods: Of the 41 mothers with positive serum HBsAg and HBeAg, 23 cases injected HBIG 600IU at 7,8,9 months of pregnancy (study group) and 18 cases not injected (control group), postpartum HBV-DNA in venous blood, colostrum, and saliva were examined by fluorescence quantitative polymerase chain reaction (FQ-PCR) and analyze them. By self-contrast comparison before and after HBIG 600Iu injection at the same period, quantitative HBV-DNA in part of study group(14 cases) were detected by FQ-PCR and analyze them. Result: The postpartum HBV-DNA positive rates of study group were significantly lower than those of control group in venous blood(X2=9.50 P<0.01) colostrum (X2=10.598 P<0.01) and saliva(X2=10.598 P=0.01); the level of HBV-DNA in mothers with HBsAg ,HBeAg positive serum were greatly decreased after HBIG injection (F=1.418 P=0.01). Conclusion: the quantitative variance of HBV-DNA with HBV carrier mothers can evaluate exactly the efficacy of HBIG. The deseasing quantitation of HBV-DNA will help toreduce the positive rate of colostrum and saliva.